Targeting the Complement Cascade: A Novel Therapeutic Strategy for Metastatic Melanoma

针对补体级联：转移性黑色素瘤的新型治疗策略

• 批准号: nhmrc : GNT1103951
• 负责人: A/Pr Trent Woodruff
• 金额: $ 54.65万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-complement-cascade-metastatic-melanoma/1346318
• 关键词: Targeting; Complement; Cascade; Novel; Therapeutic

The incidence of melanoma is increasing world-wide, and Queensland has the highest rate of melanoma in the world. Despite advances in treatment, the 3-year survival rate for metastatic melanoma remains extremely low. This project builds on our recent research demonstrating a role for a key component of the innate immune system (complement C3a) in melanoma growth. Specifically we seek to investigate the potential of C3a as a therapeutic target for metastatic melanoma.

黑色素瘤的发病率在世界范围内不断增加，昆士兰州的黑色素瘤发病率在世界上最高。尽管治疗取得了进展，但转移性黑色素瘤的3年生存率仍然极低。该项目建立在我们最近的研究基础上，该研究证明了先天免疫系统的关键成分（补体C3a）在黑色素瘤生长中的作用。具体而言，我们试图研究C3a作为转移性黑色素瘤治疗靶点的潜力。